Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Cash: 2011-2025

Historic Change in Cash for Fennec Pharmaceuticals (FENC) over the last 14 years, with Sep 2025 value amounting to $3.2 million.

  • Fennec Pharmaceuticals' Change in Cash rose 218.58% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year decrease of 165.80%. This contributed to the annual value of $13.4 million for FY2024, which is 227.23% up from last year.
  • Fennec Pharmaceuticals' Change in Cash amounted to $3.2 million in Q3 2025, which was up 181.66% from -$4.0 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Change in Cash high stood at $37.9 million for Q1 2024, and its period low was -$13.7 million during Q4 2024.
  • Over the past 3 years, Fennec Pharmaceuticals' median Change in Cash value was -$3.4 million (recorded in 2023), while the average stood at -$166,091.
  • Over the last 5 years, Fennec Pharmaceuticals' Change in Cash had its largest YoY gain of 804.22% in 2024, and its largest YoY loss of 1,673.10% in 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' Change in Cash (Quarterly) stood at -$3.0 million in 2021, then rose by 20.93% to -$6.0 million in 2022, then soared by 114.55% to $870,000 in 2023, then crashed by 1,673.10% to -$13.7 million in 2024, then skyrocketed by 218.58% to $3.2 million in 2025.
  • Its Change in Cash stands at $3.2 million for Q3 2025, versus -$4.0 million for Q2 2025 and -$4.0 million for Q1 2025.